Ask about this productRelated genes to: OCIL antibody
- Gene:
- CLEC2D NIH gene
- Name:
- C-type lectin domain family 2 member D
- Previous symbol:
- -
- Synonyms:
- LLT1, CLAX, OCIL
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 2005-02-09
- Date modifiied:
- 2015-12-16
Related products to: OCIL antibody
Related articles to: OCIL antibody
- Diabetic nephropathy (DN) is widely recognized as the primary cause of end-stage renal disease. However, the underlying mechanisms and pathogenesis of DN remain incompletely understood. Exploring novel biomarkers aiding in tracking the progression of DN has important clinical implications. - Source: PubMed
Zhao ShengLi YuejiaoLi WenchuanDong LanLian RongLuo QingqingLian XingjiLi JianboHe Feng - The lack of reliable diagnostic tools and relapse monitoring for latent tuberculosis infection (LTBI) constitutes a major obstacle to global tuberculosis (TB) control. This highlights an urgent need for robust animal models and predictive biomarkers. To address this, we report the successful establishment of a rapid murine model of recapitulating the active, latent, and relapse phases of TB within a compressed ten-week timeframe-hence termed the rapid multi-stage TB murine model. In this model, mice were first intravenously infected with , followed by a four-week isoniazid (INH) regimen starting at two weeks post-infection. By week six, pulmonary bacterial loads in most mice dropped below the detection limit, signifying the establishment of latency. Reactivation was subsequently triggered by a four-week administration of anti-TNF-α (Tumor Necrosis Factor-α) monoclonal antibody. Leveraging this reproducible and time-efficient model, we performed transcriptomic profiling of peripheral blood and identified a distinct sixteen-gene signature (including , , , , , , , , , , , , , , , ) that dynamically tracks disease progression. Collectively, these findings not only provide a valuable and efficient preclinical tool but also deliver transformable candidate biomarkers with immediate potential to guide the development of novel diagnostic strategies for LTBI surveillance and management. - Source: PubMed
Publication date: 2026/03/11
Li HaifengWang JunfeiWang YuLiu FanTang JunSun MengmengZhan Lingjun - HPV status is a key prognostic determinant in head and neck squamous cell carcinoma (HNSCC), yet the immunological mechanisms underlying the survival advantage of HPV-positive (HPV) over HPV-negative (HPV) disease remain poorly defined. This study aimed to characterize the tumor-infiltrating natural killer (NK) cell landscape in HPV-stratified HNSCC and identify novel therapeutic targets. We performed an NK-cell-centric re-analysis of published scRNA-seq data from 28 HNSCC patients (10 HPV, 18 HPV; GEO: GSE139324, GSE164690), encompassing NK subset identification, pseudotime trajectory inference, and cell-cell interaction analysis. Key findings were validated by immunohistochemistry (IHC) in an independent cohort of 10 FFPE tissue sections, and prognostic associations were assessed using TCGA-HNSC data. Four transcriptionally distinct NK cell subsets were identified: adaptive, cell-killing, CD56, and virus-responsive. A cytotoxic CX3CR1KLRB1 NK subset was specifically enriched in HPV tumors and independently associated with favorable survival. Conversely, HPV tumors upregulated CLEC2C and CLEC2D ligands on tumor cell surfaces, engaging the inhibitory receptor KLRB1 on NK cells; this CLEC2-KLRB1 axis correlated with suppressed NK activity and poorer prognosis, and was confirmed at the protein level by IHC. NK cell function in HNSCC is dichotomously regulated by HPV status. The CX3CR1KLRB1 subset represents a candidate prognostic biomarker in HPV disease, and the CLEC2-KLRB1 axis is a targetable immune evasion mechanism in HPV HNSCC. These insights support the development of HPV-stratified immunotherapies; however, clinical translation requires validation in large, prospectively designed, subsite-matched cohorts to disentangle HPV-specific effects from anatomical site-dependent immune contextures. - Source: PubMed
Publication date: 2026/03/05
Li RuiTong FangjiaLiu HuanLiu ZengchenLi WanlinZhang YingdongPeng YimanPan ShuangWei LanlanLi NingChu Ming - While immune cells are pivotal in clear cell renal cell carcinoma (ccRCC), functional alterations of specific subsets and their prognostic implications remain unclear. We aimed to identify key immune cells, characterize their functional states, and develop a prognostic model by integrating single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq) data. - Source: PubMed
Publication date: 2025/10/28
Wu YuhaiZhang YantaoSun KeNiu WenjieMei YanhuiZhu ShimiaoQuan Changyi - C-type lectin-like domain family 2 (CLEC2D), a transmembrane protein, is a ligand for the inhibitory receptor CD161, which is expressed in several types of immune cells. CLEC2D expressed on cancer cells suppresses antitumor effect of these cells by interacting with CD161 in human malignancies. However, its clinical significance in breast cancer and its direct biological role in cancer cells remain largely unclear. - Source: PubMed
Publication date: 2025/09/12
Yamaguchi-Tanaka MioKurihara YuiTakagi KiyoshiSato AiYasuda IoriYamazaki YutoMiyashita MinoruSuzuki Takashi